Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 14/20 | 0.71 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.54 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.54 |
| ▸ | TYK2 | P29597 | 2/20 | 0.54 |
| ▸ | JAK3 | P52333 | 2/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.49 |
| ▸ | CDC7 | O00311 | 1/20 | 0.49 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.49 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.49 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485141 | 0.87 | PDPK1 (0.71) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL10213932 | 0.85 | JAK2 (0.72) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL10213929 | 0.84 | JAK2 (0.81) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL3359889 | 0.83 | JAK2 (1.00) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL12907246 | 0.83 | JAK2 (1.00) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL12907433 | 0.83 | MKNK1 (0.51) | JAK2TYK2JAK3JAK1CYP3A4 | |
| SCHEMBL10130802 | 0.81 | JAK2 (0.60) | JAK2PDPK1TYK2JAK3JAK1 | |
| SCHEMBL22715912 | 0.81 | JAK2 (0.71) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL12907180 | 0.81 | JAK2 (0.71) | JAK2PDPK1MAP4K4TYK2JAK3 | |
| SCHEMBL12907221 | 0.81 | JAK2 (0.71) | JAK2PDPK1MAP4K4TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053345-A1 | Indazole Compounds | ABBOTT LABORATORIES (US) | 2012-03-01 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-8008481-B2 | Indazole compounds | ABBVIE INC. | 2011-08-30 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| US-7872039-B2 | N-3-chlorobenzyl-3-amino-1H-indazole-5-carboxamide; 3-aminoindazoles; glucocorticoid-depedent kinase (SGK) inhibitors; SGK-induced diseases; diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and renal diseases, fibrosis; inflammatory agents | MERCK PATENT GESELLSCHAFT (DE) | 2011-01-18 | — | — | US | disclosed |
| EP-1765788-B1 | 3-AMINOINDAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SGK-ASSOCIATED DISEASES | MERCK PATENT GMBH (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070282101-A1 | Indazole compounds | ABBVIE INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
| US-20070232620-A1 | 3-Aminoindazoles | MERCK PATENT GMBH (DE) | 2007-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070282101-A1 | Indazole compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885PDPK1 856/4885MAP4K4 2140/4885 |
| US-20120053345-A1 | Indazole Compounds | CYP3A43, CYP3A7, UGT1A1 | JAK2 1822/4885PDPK1 856/4885MAP4K4 2140/4885 |
| US-20070232620-A1 | 3-Aminoindazoles | SGK3, SGK1, SGK2 | JAK2 562/4885PDPK1 118/4885MAP4K4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.